Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma

By Colin Kellaher

Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.

The companies on Friday said the FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.

Abecma was previously approved for adults after four or more prior lines of therapy.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

04-05-24 0932ET